TriangleAutologous Hematopoietic Stem Cell… (NCT07605416)
Autologous Hematopoietic Stem Cell Transplantation trial for Plasma Cell Leukemia (NCT07605416). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults aged 18–80 with primary plasma-cell leukemia and no more than one prior induction cycle.
The idea: give daratumumab, carfilzomib, lenalidomide and dexamethasone, followed by melphalan and the patient's own stem-cell transplant. Then compare further four-drug treatment with teclistamab, which directs T cells to BCMA-bearing cancer cells. Both groups later receive carfilzomib and lenalidomide maintenance. Researchers compare survival and safety; marrow samples track residual disease.
This phase 2 study plans 74 patients. Douglas Sborov leads through Alliance; 11 US locations list recruitment.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.